HighTower Advisors
ANIK icon

HighTower Advisors’s Anika Therapeutics ANIK Stock Holding History

HighTower Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,971
Closed -$315K – 3765
2025
Q1 		$315K Buy
20,971
+7,618
+57% +$127K ﹤0.01% 2822
2024
Q4 		$220K Sell
13,353
-2,530
-16% -$49.9K ﹤0.01% 3125
2024
Q3 		$387K Buy
15,883
+1,615
+11% +$41.9K ﹤0.01% 2614
2024
Q2 		$361K Buy
14,268
+292
+2% +$7.57K ﹤0.01% 2571
2024
Q1 		$356K Buy
13,976
+3,534
+34% +$85.5K ﹤0.01% 2549
2023
Q4 		$239K Buy
+10,442
New +$216K ﹤0.01% 2887
2021
Q1 		– Sell
-9,462
Closed -$425K – 3047
2020
Q4 		$425K Buy
9,462
+617
+7% +$23.4K ﹤0.01% 1708
2020
Q3 		$314K Buy
8,845
+991
+13% +$35.8K ﹤0.01% 1810
2020
Q2 		$298K Buy
7,854
+1,035
+15% +$34.1K ﹤0.01% 1741
2020
Q1 		$200K Buy
+6,819
New +$276K ﹤0.01% 1790
2019
Q4 		– Sell
-4,204
Closed -$230K – 2327
2019
Q3 		$230K Buy
+4,204
New +$216K ﹤0.01% 1972

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return

HighTower Advisors's ANIK Position: Q2 2025 in Review

HighTower Advisors sold out of Anika Therapeutics (ANIK) in Q2 2025, closing a stake of 20,971 shares — an estimated $315K sold.

HighTower Advisors first reported a position in ANIK in Q3 2019 and held it in 11 quarters. The position peaked at $425K in Q4 2020. 103 funds tracked by Wall St. Rank hold ANIK as of Q2 2025.

  • HighTower Advisors reported no remaining Anika Therapeutics position as of Q2 2025 after selling out during the quarter.
  • HighTower Advisors sold 20,971 Anika Therapeutics shares in Q2 2025, an estimated $315K.
  • HighTower Advisors first reported a position in Anika Therapeutics in Q3 2019 and held it in 11 quarters.
  • HighTower Advisors's Anika Therapeutics position peaked at $425K in Q4 2020.
  • 103 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2025.

Based on HighTower Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.